CONNECT WITH US:
Jan, 28 2019 13:00 JST
Singapore eDevelopment Ltd
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
SINGAPORE, Jan, 28 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has tested 3F Antimicrobial Fragrance which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world's population.
The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. Experiments were performed at ATCC as a custom service within its High Containment Laboratory under BioSafety Level 3 conditions. ATCC is a premier biological materials and information resource and standards organization with expertise in handling and experimentation on dangerous pathogens such as MTB.
Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F Antimicrobial Fragrance. "3F works by taking advantage and exploiting the bacterial or viral sophisticated communication system called quorum sensing.
"In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.The 3F project was designed to provide a solution for open environment defence strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective."
"As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB," said Dr. Manzour Hazbon, ATCC Senior Scientist. "This fragrance is very effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases."
Mr Chan Heng Fai, Executive Chairman of SeD said, "We are excited about the potential of this breakthrough in 3F Antimicrobial, and Global BioLife will step up in its continued efforts to provide cutting edge research into real solutions for global healthcare problems."
Dr. Roscoe M. Moore Jr, former Senior Assistant Surgeon General of the U.S. and highly-regarded public health expert who serves as Senior Scientific Adviser to Global BioLife, says "I'm excited about 3F's potential to address a global epidemic by providing safe and versatile protection layers."
"Tuberculosis is a global priority and Global BioLife's solution will help save lives on a global scale." Dr. Moore also served as Epidemic Intelligence Service Officer with the U.S. Center for Disease Control and Prevention, and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration.
Also advising Global BioLife is Lieutenant Colonel William H. Lyerly Jr., a former Scientific Professional (ST) with the U.S. Government Civil Service and retired U.S. Army Medical Service Corps Officer with an extensive medical background including disaster relief, development, biodefense, interagency and civilmilitary cooperation and teaching.
"As TB's person-to-person spread requires only a small number of bacteria and transmission is most rapid in confined spaces, 3F efficacy is especially promising. And as multidrug-resistant TB continues a global health crisis and security threat, 3F's environmental intervention represents an effective and less-costly TB control strategy in high-transmission areas worldwide."
Global Biolife has partnered with Destum Inc to license its 3F technology to global manufacturers and distributers. 3F Mosquito, unlike repellents such as DEET, was developed as an additive to laundry detergents and lotions for layered protection against mosquitos. 3F Antimicrobial was developed as an additive for sprays, filters and dispersal systems in hospitals, transit and open areas to protect against bacteria and viruses.
Global BioLife (GBLI) is 70%-held by Global BioMedical, owned by Singapore BioMedical Ltd, owned by Singapore eDevelopment. 20% held by Global Research & Discovery Group LLC (GRDGS) and 10% by ASX-listed Holista CollTech. Tapping GRDGS & Holista expertise, GBLI pledges a concerted effort at prevention and treatment of neurological, oncology and immuno-related diseases. See www.globalbiolife.com.
GRDGS LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, visit www.globalrdg.com.
Singapore eDevelopment (SGX:V40), www.SeD.com.sg or
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
SDK Receives Award for Used-Plastic Chemical Recycling Business
Feb 28, 2020 16:00 JST
SDK Announces Progress Towards the Tender Offer for Shares of Hitachi Chemical Company, Ltd. (Securities Code 4217)
Feb 28, 2020 16:00 JST
NEC's Unified Communications Platform "UNIVERGE SV Series" Reaches 500,000 Shipments
Feb 28, 2020 14:32 JST
Mitsubishi Corporation and Chubu Electric Power Consortium Named Preferred Bidder for Offshore Transmission Asset in the UK
Feb 28, 2020 07:47 JST
Mazda Production and Sales Results for January 2020
Feb 27, 2020 14:03 JST
Toyota Updates Results for January 2020
Feb 27, 2020 13:35 JST
NEC Releases "Open & Virtualized RAN" White Paper
Feb 27, 2020 12:15 JST
Hitachi and Chulalongkorn University Agree on a Cooperative Relationship for Social Innovation in Thailand
Feb 27, 2020 09:44 JST
Mitsubishi Aircraft Corporation and Mitsubishi Heavy Industries Aero Engines Celebrate First Flight of First GTF Engine Produced in Japan
Feb 27, 2020 09:32 JST
NEC Partners with Juniper Networks to Enable Telefonica Chile's IP Network Fusion Project
Feb 26, 2020 16:33 JST
Lexus' Electrification Drives Sensory Experience at Milan Design Week 2020
Feb 25, 2020 18:27 JST
4 Sharp Products Win 2020 iF Design Award
Feb 25, 2020 17:37 JST
Mitsubishi Corporation and CRISP HD Agree to Business Alliance and Acquisition of Third-Party Shares
Feb 25, 2020 15:16 JST
Double Podium for TOYOTA GAZOO Racing in Austin
Feb 25, 2020 09:41 JST
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Feb 25, 2020 09:10 JST
The Closure of Automobile Production in the Philippines
Feb 22, 2020 18:00 JST
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
Feb 21, 2020 17:55 JST
MHPS Receives 12 Year Maintenance Service Extension for the BLCP Power Station in Thailand
Feb 21, 2020 16:07 JST
Toyota and Toyota Industries Jointly Develop New Battery for Hybrid Electric Vehicles
Feb 20, 2020 14:27 JST
NEC and Accedian partner globally to address network performance visibility challenges and predictive analytics requirements
Feb 20, 2020 13:03 JST
More Latest Release >>
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
November 15 2019 02:00 JST
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
October 29 2019 09:00 JST
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
July 24 2019 15:00 JST
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
June 12 2019 14:00 JST
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
November 07 2018 19:00 JST
Singapore eDevelopment Limited Announces Corporate and Business Update
June 18 2018 19:00 JST
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31 2018 18:00 JST
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
March 01 2018 14:00 JST
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
November 01 2017 18:00 JST
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
October 24 2017 18:00 JST
More Press release >>